Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Jan 31, 2023 4:36pm
255 Views
Post# 35257888

RE:Waiting...

RE:Waiting...You know what.. When investors were waiting to hear about results from ONCY's first Phase III trail for head & Neck cancers, Brtad Thomson (then CEO), reassured investors that the survival curve was still progressing... and I think results were 12 months later than anticipated.

From the numbers previously presented, in essence the company was waiting on data from just one or two patients.

Brad's comments were... patients just keep living longer and longer. The longer the wait the better the results... was his mantra.

And, can you guess what happened with the results from the Phase III, that ONCY claimed was successful..? Hmmmm, let's just hope history isn't repeating eh... cause right now, all we have is hope.. and that is a dangerous place to be as an investor.

<< Previous
Bullboard Posts
Next >>